Event-Driven Stocks

Aligos Therapeutics, Inc.

ALGSNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$2.2M$3.6M$6.2M$0$0$0
Operating income−$88.0M−$89.2M−$88.1M−$97.6M−$128.3M−$97.8M
Net income−$24.2M−$131.2M−$87.7M−$96.0M−$128.3M−$108.5M
Total assets$88.5M$70.1M$151.5M$146.7M$235.4M$265.3M
Total liabilities$35.0M$99.1M$59.4M$42.8M$50.6M$45.3M
Equity$53.5M−$29.0M$92.1M$103.9M$184.7M$220.0M
EPS (diluted)$-2.45$-20.94$-34.20$-2.25——
Shares out.6.2M79.9M3.0M42.9M38.1M36.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−4024.9%
Net margin
−1106.7%
Return on equity
−45.2%
Return on assets
−27.3%
Return on capital (ROCE)
−130.7%
Liabilities / assets
39.5%
Debt / equity
0.65×
Book value / share
$8.67
Revenue growth (YoY)
−39.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-24.15distress
Accruals / assets
65.9%high accruals
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
28
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026535,1773.5+9.3%
Apr 30, 2026489,6331.0+77.6%
Apr 15, 2026275,6894.5-10.0%
Mar 31, 2026306,1767.6+3.8%
Mar 13, 2026294,8426.5+1.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.